Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16 USD | -3.61% | -12.38% | -25.44% |
Apr. 09 | UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating | MT |
Apr. 03 | Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.44% | 2.36B | |
-3.10% | 102B | |
+2.11% | 96.07B | |
-1.80% | 21.66B | |
-17.75% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.19% | 13.79B | |
+0.18% | 13.33B | |
+19.90% | 10.94B |
- Stock Market
- Equities
- DNLI Stock
- News Denali Therapeutics Inc.
- Denali Therapeutics : HC Wainwright Adjusts Denali Therapeutics' Price Target to $95 From $80, Keeps Buy Rating